On April 1, 2019 PharmaMar (PHM:MSE) reported that it has been notified by the lead author, Dr. Luis Paz-Ares, MD, PhD, Professor of Medicine at the Hospital Universitario 12 de Octubre in Madrid, Spain, that the abstract titled "Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial" has been accepted by ASCO (Free ASCO Whitepaper) (American Society of Clinical Oncology) and has been selected for an oral presentation at the 19th Annual Meeting in Chicago, Illinois (Press release, PharmaMar, APR 1, 2019, View Source [SID1234534827]). Dr. Paz-Ares will present the data on June 1st.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this oral presentation, the results referring to the phase II study of lurbinectedin, in monotherapy, with the 105 patients who have participated will be made public.

PharmaMar has already announced that the trial met its primary endpoint, as determined by both the investigator and the IRC (Independent Review Committee) assessments.

Dr. Paz-Ares and PharmaMar management will host a conference call after the data presentation. More details will follow in due course.

Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction